Ageing Research Reviews Impact Factor

For a review journal, the most useful metric here is not the headline JIF alone. It is the combination of a 15.5 two-year JIF and a 17.5 five-year JIF.

That spread matters. It tells you the better ARR papers keep getting used after the first citation wave. In aging research, that usually means reviews that organize a mechanism cleanly, reset how people think about an intervention, or clarify a muddled disease-biology question.

The journal's annual volume and article-type mix also matter. Elsevier describes Ageing Research Reviews as a home for critical reviews, short reviews, and viewpoints on mechanisms of ageing and age-related disease. ARR is not trying to publish every competent aging review. It favors reviews that feel field-defining enough to become standard starting points for later work.

That is why the 15.5 should not be read as permission to submit any review with aging keywords. The number says the journal is visible and heavily cited; it does not say the manuscript has made a field-level judgment. A strong ARR review usually has a thesis that could be diagrammed in one figure: which mechanism matters, which evidence class is strong, which intervention claim is premature, or which disease link changes how aging biologists should frame the next experiment.

Because ARR is review-heavy, the JCR figure should lead the decision. The longer table uses Resurchify's Scopus impact-score history to show whether aging-review citation demand is moving with or against the current JIF.

Directionally, the open citation signal is up from 13.35 in 2023 to 13.60 in 2024, and materially up from the 2014 to 2017 range. That matches the journal's current status as one of the more trusted synthesis venues in aging biology.

The better way to read that trend is not "aging is hot, so the number is high." It is that aging reviews have become more useful as the field has become more mechanistic, more translational, and more crowded. A review that actually clarifies the field now gets cited heavily because the noise level is higher.

Rank rows can change when Clarivate updates category counts, journal coverage, or denominator labels. Use current JCR for current-facing citation and avoid copying older rank rows into new copy without checking the live denominator.

The mistake is to assume any well-written review on aging belongs here because the journal is review-only.

That is not the editorial bar. ARR does best when the manuscript does one of four things clearly:

• reorganizes a live mechanistic debate

• sharpens how a disease or intervention should be understood through the aging lens

• separates hype from durable evidence

• gives readers a framework they can actually use in future research

A broad narrative overview can still be publishable somewhere else. It just often is not enough for ARR.

Elsevier's current issue sample is useful because it shows how broad the aging label can be while still needing a review-level argument. Recent ARR articles include neurodegeneration treatment mechanisms, blood-based Alzheimer disease biomarkers, longevity ethics, biological-age organ asynchrony, multimorbidity and polypharmacy guidelines, adiponectin and aging, neuroimmune dysregulation, and epigenetic markers of aging and cancer risk.

Across our Ageing Research Reviews pre-submission reviews, the metric is rarely the blocker. In our review work on ARR-targeted manuscripts, the weaker part is usually whether the abstract, literature-search method, figure package, evidence tables, references, and cover letter prove that the review is more than a polished topic overview. Editors at ARR usually want sharper intellectual compression: the manuscript should help readers decide what the field believes, where the evidence is thin, and what should happen next.

Ageing Research Reviews reviews that describe instead of decide. The manuscript summarizes papers but never tells the reader which mechanisms, models, or interventions hold up best. The abstract may be accurate, and the section headings may be logical, but the review still reads like an annotated bibliography. ARR fit is stronger when the tables and figures force a judgment about which evidence is durable.

Ageing Research Reviews topics that are too wide for one coherent argument. Aging, senescence, metabolism, immunity, and disease are all relevant, but piling them together rarely produces a review editors can route confidently. We look for whether the introduction names one governing question and whether each figure, table, and subsection serves that question instead of expanding the literature map indefinitely.

Therapeutic language that outruns the evidence. This is common in longevity and intervention reviews. The manuscript starts making translational promises that the cited evidence cannot support cleanly. For ARR, the safer move is to separate mechanistic plausibility, animal-model evidence, human biomarker evidence, and clinical readiness rather than letting the discussion imply one continuous path to intervention.

Search and selection logic that is under-explained. Even a narrative review needs enough method discipline that editors trust the synthesis was not assembled opportunistically. The manuscript should make database choice, date range, inclusion logic, exclusion logic, and citation-update timing visible enough that a reader can understand why these studies, not a convenient subset, define the argument.

Article-type mismatch hidden inside a strong topic. Elsevier lists Review Article, Short Review, and View Point formats. We see ARR-targeted manuscripts struggle when a 2,500-word short review is carrying a full field map, or when a View Point lacks enough evidence boundary to read as more than opinion. The article type should match the abstract promise, figure count, and literature method.

If those problems still describe the paper, an Ageing Research Reviews submission readiness check is usually more useful than another round of line editing.

• Ageing Research Reviews submission guide

• Aging Cell submission guidelines

• How to find a journal's impact factor

• Do I need pre-submission review?

For a concrete benchmark, browse sample reports before sending an aging-review manuscript to ARR.

Once a submission reaches the portal, the Ageing Research Reviews Under Review status guide interprets the holding period and what the label does and does not tell you.